Regeneron: Solid Trial Takes Targets Up, Up, Up

Shares of Regeneron (REGN) have surged today after the biotech company said an anti-cholesterol drug performed well in a drug trial. Bloomberg has the details: In the largest of the four trials, among 2,341 patients, those receiving the drug, alirocumab, had a 62 percent reduction in their levels of bad cholesterol after six months of [...]